



Dialysis Access—A New Era

Guest Editors:

Prof. Dr. Toshihide Naganuma

Prof. Dr. Yoshiaki Takemoto

Prof. Dr. Junji Uchida

Prof. Dr. Hideki Kawanishi

Deadline for manuscript
submissions:

closed (31 May 2021)

Message from the Guest Editors

Every year, the Japanese Society for Dialysis Access (JSDA) runs a conference to bring together doctors, clinical engineers, nurses, and medical companies relating to dialysis access.

JSDA2020 was held in Osaka on 27th and 28th November during the ongoing COVID-19 pandemic, and the one-month online viewing period (on demand) ended on 15th January 2021.

Because drug-coated balloon (DCB) will soon be available for vascular access in Japan, we have invited specialists to the international symposium (JSDA-KSDA joint symposium) from Korea where DCB is already used. Their experience will certainly be useful and helpful for doctors who will be using DCB in Japan, and all other countries considering an introduction to this new technique.

The issue will comprise invited articles from selected presentations from our meeting, including the international symposium.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Francesco Locatelli
Department of Nephrology and
Dialysis, Alessandro Manzoni
Hospital, Lecco, Italy

Message from the Editor-in-Chief

In recent years, we have been witnessing dramatically increased interest in the treatment of chronic kidney disease, e.g., diabetic kidney disease, glomerular disease, or autosomal dominant polycystic kidney disease, but also aimed more generally on the progression of chronic kidney disease and the complications of chronic kidney disease, such as anemia, or hyperkalemia. This progress has led to changing paradigms as reflected by several recently published KDIGO guidelines which now need to be updated much more frequently than before. To personalize treatment, we also need better diagnostic methods, including validated biomarkers reflecting the activity of the disease (including response to treatment) and predicting outcomes.

Kidney and Dialysis aims to cover most of these areas not only in terms of feature reviews, but also original articles, and to keep the reader updated on recent progress in nephrology and dialysis.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **ESCI (Web of Science)**, **Scopus** and **other databases**.

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 53.2 days after submission; acceptance to publication is undertaken in 5.9 days (median values for papers published in this journal in the first half of 2024).

Contact Us

Kidney and Dialysis Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/kidneydial
kidneydial@mdpi.com
[X@Kidneydial_MDPI](https://twitter.com/Kidneydial_MDPI)